These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20139393)

  • 1. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M
    Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 5. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
    Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
    Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
    Richardson PG; Laubach JP; Schlossman RL; Mitsiades C; Anderson K
    J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S4-S12. PubMed ID: 20141673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
    Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma.
    Crawford CL
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736295
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Palumbo A; Mateos MV; Bringhen S; San Miguel JF
    Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 17. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
    Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
    Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.